Active Ingredient History
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor discovered by Boehringer Ingelheim and being developed as an oral once-daily tablet for the treatment of Type 2 diabetes. Linagliptin was first approved by FDA in 2011 under the trade name Tradjenta as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Linagliptin binds to DPP-4 (an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) in a reversible manner and thus increases the concentrations of incretin hormones. Linagliptin glucose dependently increases insulin secretion and lowers glucagon secretion, thus resulting in better regulation of glucose homeostasis. Linagliptin binds selectively to DPP-4, and selectively inhibits DPP-4 but not DPP-8 or DPP-9 activity in vitro at concentrations approximating therapeutic exposures. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Albuminuria (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Coronary Artery Disease (Phase 4)
Coronavirus (Phase 3)
Coronavirus Infections (Phase 4)
COVID-19 (Phase 3)
Dipeptidyl-Peptidase IV Inhibitors (Phase 3)
Endocrine System Diseases (Phase 3)
Esophageal Neoplasms (Phase 2)
Glucose Intolerance (Phase 4)
Glucose Metabolism Disorders (Phase 3)
Glycation End Products, Advanced (Phase 4)
Healthy Volunteers (Phase 1)
Heart Failure, Diastolic (Phase 3)
Hepatic Insufficiency (Phase 1)
Hormones (Phase 3)
Hyperglycemia (Phase 3)
Hypertension (Phase 3)
Hypertrophy, Left Ventricular (Phase 3)
Hypoglycemic Agents (Phase 3)
Incretins (Phase 3)
Inflammation (Phase 3)
Insulin Resistance (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Linagliptin (Phase 3)
Metabolic Diseases (Phase 3)
Osteoporosis (Phase 4)
Peritoneal Dialysis (Phase 4)
Prediabetic State (Phase 4)
Renal Insufficiency (Phase 2)
Respiratory Tract Diseases (Phase 3)
SARS-CoV-2 (Phase 3)
Schizophrenia (Phase 4)
Sodium-Glucose Transporter 2 Inhibitors (Phase 4)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
